Dexasone
Fabry Disease
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sanofi
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06019728CT.gov A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fabry Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Sanofi | Approved | BB · 66 |
| Recombinant Alpha-Galactosidase A | Shire | P4 | A |
| Agalsidase Beta | Sanofi | P4 | A |
| Pegunigalsidase Alfa | Chiesi Italia | P3 | BBB |
| Migalastat | Amicus Therapeutics | P3 | BBB |
| Montelukast | Sanofi | P4 | BB |
| Loratadine | Sanofi | P4 | BB |
| Fexofenadine | Sanofi | P4 | BB |
| Lucerastat | Idorsia Pharmaceuticals Ltd. | P3 | BB |
+28 more in the Fabry Disease cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Fabry Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-fabry-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →